Interpreting ReoPro's EPILOG results

Investigators presented final six-month data from the EPILOG trial of Centocor Inc.'s ReoPro GPIIb/IIIa inhibitor in all comers undergoing angioplasty. As reported Sunday at the American Heart Association meeting in New Orleans, the composite end point of death, myocardial infarction and repeat revascularization was statistically significant at six months, maintaining the benefit seen at 30 days.

The number of deaths and heart attacks were reduced by 46 percent at six months. Death rates were reduced by 6 for every 1,000 patients, and 49 fewer heart attacks occurred per 1,000 patients...